



Date: 30.05.2026

To,
The Manager, Listing Department,
National Stock Exchange of India Limited
Exchange Plaza, C-I Block G, Bandra Kurla Complex, Bandra (East),
Mumbai-400051, Maharashtra, India.

Scrip Symbol: CURIS ISIN: INE1BZN01016

Dear Sir/ Ma'am,

Subject: Statement of Deviation or Variation in utilization of funds raised under Regulation 32 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 for the half-year and financial year ended on March 31, 2026 of the Financial Year 2025-26:

Pursuant to Regulation 32 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are presenting herewith the Statement of Deviation or Variation in utilization of funds raised through Initial Public Offering (IPO) for the half- year and financial year ended on March 31, 2026 pertaining to Financial Year 2025-26 as per the details provided in **Annexure-A**.

You are requested to take the above information on record and disseminate the same for the information of the stakeholders.

Thanking you,
Yours faithfully,

FOR CURIS LIFESCIENCES LIMITED

JAIMIK MANSUKHLAL PATEL
WHOLE-TIME DIRECTOR
DIN: 07371003



ANNEXURE -A

STATEMENT ON DEVIATION OR VARIATION FOR PROCEEDS OF INITIAL PUBLIC OFFERING (IPO)

Statement on deviation / variation in utilisation of funds raised	
Name of the Listed Entity	Curis Lifesciences Limited
Mode of Fund Raising	Public Issue (Book Built SME IPO)
Date of Raising Funds	November 14, 2025 <i>(Date of Listing)</i>
Amount Raised	₹27.52 Crores (21,50,000 Equity Shares at ₹128 each)
Report filed for year ended	March 31, 2026
Monitoring Agency	Not Applicable
Monitoring Agency Name, if applicable	Not Applicable
Is there a deviation/ Variation in use of fund raised	No
If yes, whether the same is pursuant to change in terms of contract or objects which was approved by the shareholder	NA
If Yes, Date of shareholder approval	NA
Explanation for deviation / variation	NA
Comments of the Audit Committee after review	NA
Comments of the auditors, if any	NA



(In Lakhs)

Original Object	Modified Object if any	Original Allocation (Rs. In Crores)	Modified allocation, if any	Funds Utilised (Rs. In Crores)	Amount of Deviation/ Variation for the quarter according to the applicable object	Remarks if any
Capital Expenditure towards Upgradation/Improvement of our existing Manufacturing Facilities	-	244.27	-	0.00	-	-
Capital Expenditure towards Construction of a Storage Facility	-	361.99	-	100.00	-	-
Pre-payment/Repayment of outstanding Secured Loans	-	186.45	-	182.33	-	-
Product Registrations in other countries	-	269.30	-	0.00	-	-
Funding our Working Capital Requirements	-	1,125.00	-	1,125.00	-	-
General Corporate Purpose	-	284.99	-	289.11	-	-
Issue Related Expenses	-	280.00	-	*359.63	-	-
Total		2,752.00		2,056.07	-	-



***Note:** During the period under consideration, the company incurred excess amount of Rs. 79.63 lacs for Issue Related Expenses and same is not considered for negative amount in unutilized amount.

Also, EMI of Rs. 4.12 lacs were debited by the bank in period between filing of offer document and receipt of issue proceeds, therefore, that amount of shortfall in 'Pre-payment/Repayment of outstanding Secured Loans' purpose is reflected in 'General Corporate Purpose'.

Further, during the period the company has made several advance payments in relation to above purposes but due Bill/Invoice not being received, it shall be considered as utilized only upon accounting of such Asset/Expenses against those advances paid.

Statement of Utilization of Issue Proceeds

Statement of Utilization of Money raised through Issue of Initial Public Offer of Equity Shares for the period ended March 31, 2026

On the basis of Books of Accounts, other documents and explanations provide before us by the management, we hereby certify that M/s Curis Lifesciences Limited (CIN: L24230GJ2016PLC086559) having its registered factory at PF 23, Sanand GIDC-II, Sanand, Ahmedabad - 382110 Gujarat, India has utilised proceeds of Fresh Issue for the stated purpose in offer document dated 11th November, 2025 during the period from 15th November, 2025 to 31st March, 2026 as given in the below table:

(Rs. In Lakhs)

Sr. No.	Object as stated in the Offer Document	Amount proposed to be utilized	Amount utilized during period	Unutilized Amount
1.	Capital Expenditure towards Upgradation/Improvement of our existing Manufacturing Facilities	244.27	0.00	244.27
2.	Capital Expenditure towards Construction of a Storage Facility	361.99	100.00	261.99
3.	Pre-payment/Repayment of outstanding Secured Loans	186.45	182.33	4.12
4.	Product Registrations in other countries	269.30	0	269.30
5.	Funding our Working Capital Requirements	1,125.00	1,125.00	0.00
6.	General Corporate Purpose	284.99	289.11	(4.12)
7.	Issue Related Expenses	280.00	359.63	0.00*
Total		2,752.00	2,056.07*	775.56

Above certificate is issued at request from the management of the company and for restricted use of regulatory compliances purpose with BSE, SEBI, etc. Accordingly, we do not accept or assume any liability or any duty of care for any other purpose or to any other person to whom this certificate is shown or into whose hands it may come without our prior consent in writing.



***Note:** During the period under consideration, the company incurred excess amount of Rs. 79.63 lacs for Issue Related Expenses and same is not considered for negative amount in unutilized amount.

Also, EMI of Rs. 4.12 lacs were debited by the bank in period between filing of offer document and receipt of issue proceeds, therefore, that amount of shortfall in 'Pre-payment/Repayment of outstanding Secured Loans' purpose is reflected in 'General Corporate Purpose'.

Further, during the period the company has made several advance payments in relation to above purposes but due Bill/Invoice not being received, it shall be considered as utilized only upon accounting of such Asset/Expenses against those advances paid.

For, B T Vora & Co.

Chartered Accountants
FRN: 123652W



C. A. SHETH

PARTNER

M. No. 180506

UDIN: 26180506FAOZFE8617

Place: Ahmedabad

Date: 30.05.2026